GET DAILY SIGNALSChurch & Dwight (CHD): What to Expect from Q1 2026 Earnings
Key Takeaways
- Analysts expect Q1 2026 EPS (earnings per share) of $0.93, reflecting 2.2% year-over-year growth.
- Consensus revenue estimate stands at $1.47 billion, approximately flat compared to Q1 2025's $1.467 billion.
- Church & Dwight has beaten EPS estimates in the trailing four quarters by an average of 6.6%.
- Full-year 2026 adjusted EPS guidance targets 5% to 8% growth over 2025.
- Investors will watch organic sales growth, gross margins, and updates on key categories like personal care and household products.
- Recent Q4 2025 results showed 3.9% net sales growth, supporting momentum into the new year.
Earnings Context and Why It Matters
Church & Dwight (CHD), a leading consumer staples company known for brands like Arm & Hammer, OxiClean, and Trojan, faces a pivotal Q1 2026 earnings report amid shifting consumer dynamics. The company has navigated volume pressures in mature categories through pricing actions and innovation, delivering consistent profitability. With shares trading around $95 after peaking near $106 earlier this year, this report will gauge early progress toward full-year goals. From what I see, it offers key insights for investors into demand resilience, margin trends, and the impact of recent acquisitions like Touchland hand sanitizer, especially as peers report mixed consumer spending signals.
Earnings Expectations
Wall Street anticipates Q1 2026 revenue of $1.47 billion for CHD, implying a slight dip or flat performance versus Q1 2025's $1.467 billion, driven by potential softness in volumes offset by pricing. EPS consensus is $0.93, up from $0.91 adjusted in the year-ago quarter. This reflects expectations of steady gross margins around 44-45%, bolstered by supply chain efficiencies.
Key metrics in focus include organic sales growth, projected near flat after Q4 2025's 0.7% rise, and performance across segments: Consumer Domestic (76% of sales), Consumer International, and Specialty Products Division (SPD). Historically, CHD has posted strong EPS beats, with Q1 2025 adjusted EPS of $0.91 topping estimates despite a sales miss. Stock reactions have been muted to positive on beats, averaging +1-2% post-earnings over recent quarters. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Heading into Q1 earnings, sentiment leans cautiously optimistic for CHD, buoyed by the company's earnings beat streak and full-year guidance reaffirmation in January. Shares have declined about 10% from February highs amid broader consumer staples rotation, but analysts maintain a consensus "Buy" rating with a $102 target. Risks include weaker-than-expected volumes from economic headwinds or competitive pressures in laundry and oral care. In my view, a beat could spark a rebound, while an in-line or miss on sales might pressure the stock further. I’m watching Tickeron’s AI Daily Buy/Sell Signals for any shifts in real-time sentiment around earnings.
Tickeron’s AI Screener
One tool I rely on regularly in my research is Tickeron’s AI Screener, an AI-powered stock and ETF discovery tool that helps me filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. It allows scanning thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics—making it far more efficient than manual screening for identifying trade ideas, trending stocks, breakout candidates, and market opportunities. I used it here to evaluate CHD against peers, and it’s become a staple in my process.
Forward Outlook and Key Factors to Monitor
Following Q1 results, investors should track management's commentary on full-year 2026 guidance for CHD, which projects adjusted EPS growth of 5% to 8% over 2025's levels. This outlook hinges on 2-4% organic sales growth, gross margin expansion from productivity gains, and contributions from high-growth areas like hand sanitizers and pet care.
Upcoming catalysts include Q2 volume trends amid easing inflation, progress on innovation pipelines such as new Arm & Hammer formulations, and international expansion. Margin pressures from input costs or marketing investments will be scrutinized, alongside SPD performance in animal productivity and food protection.
One thing that stands out is how broader industry dynamics, including consumer health spending and retail partner inventories, remain critical. CHD's focus on everyday essentials positions it defensively, but sustained demand signals in core categories will be key to achieving guidance midpoints.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
CHD's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for CHD turned positive on October 05, 2026. Looking at past instances where CHD's MACD turned positive, the stock continued to rise in 28 of 50 cases over the following month. The odds of a continued upward trend are 56%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on CHD as a result. In 46 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 49%.
CHD moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CHD crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 38%.
Following a +4.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where CHD advanced for three days, in 166 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.
The Aroon Indicator entered an Uptrend today. In 88 of 217 cases where CHD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 41%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 48%.
CHD broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 16 (best 1 - 100 worst), indicating outstanding price growth. CHD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 42 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.955) is normal, around the industry mean (21.072). P/E Ratio (34.875) is within average values for comparable stocks, (16.552). Projected Growth (PEG Ratio) (2.688) is also within normal values, averaging (1.518). Dividend Yield (0.011) settles around the average of (0.033) among similar stocks. P/S Ratio (3.676) is also within normal values, averaging (1.902).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of sodium bicarbonate and sodium bicarbonate based products
Industry HouseholdPersonalCare
Advertisement